Spine BioPharma

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Orum, Vertex Ink Novel Protein-Deg

Korean biopharmas have walked through a tunnel of financing drought and feeble licensing deals in 2022. Although there has been certain positive R&D progress, the overall industry sentiment, especiall

For Yuhan Corporation , the past several years have marked a new beginning in terms of the development and globalization of novel drugs, and the pursuit of an open innovation approach to R&D has been

Several major South Korean pharma firms have reported mixed first-quarter earnings, affected by varied factors including continued strength in overseas performance, solid sales of key prescription dru